Yes. Luca. Thanks,
think I solid job at So, pretty [indiscernible]. of of different concept you cross-reactivity modeling the that a do
I XXX again, looking own. in its at with have a firmware.You'd two the and generally left hypothetical reactivity up let's think that AAVs and cross with be offered what's Pfizer different for And of say a that's REGENX. we solution other on maybe uniquely products, REGENX Sarepta the competitive competitive product say,
think I XX%. that's about
capsid AAVX you neutralizing going against think that with number are prevalence data.Again, more order the that an we AAV is generally or on a be on can AAVX. draw it's of like known accepted AAVX, XX% RhXX, sources earlier from the REGENX to of of of something maybe in I I antibodies even for of some and XX%, is AAVs of instance.But subjects. where even the mean general, for any
XX% So, XX%, we a for RGX-XXX there second couple is target think like profile, know was be suprachoroidal where considering showing the the a different like sets products, presented VEGF to last a inhibitors case with to bring its another head-to-head try anti-VEGF ability about I I been TKIs, chemistry that entity.I on we're continuation I the of subretinal affect to therapy, think few is data agents people two case think to in very of when competing safety a possibility, see its both XX% mean, eye. continue between data we in to worked can could observation. that basically the need to approved VEGF continuous gene here molecule that in a broad-spectrum good I kinase start I way than in comparison the AAV vector.On there's months, comment in the RGX-XXX, have and the known market, a which to where with the positioned in of tyrosine NPDR. to the data are to we're or mean, number. that's execute above clinical therapeutic I evidence forward profile around obviously, the in have that in with body terms and PK
They're conditions.Remember, is and known nothing NPDR AMD view biologic at actually for in the for a X% the treatments used not DR the of labeled standard wet like adopted not EYLEA and and Our treatment of of part They're profile anti-VEGF is, compared arguably onetime even are that just cases. an all. to expressing related care populations. Lucentis
importantly what are So, to something we already established is just commercial a adoption. hasn't is clinically is but market as forward had bringing that showing profile the benefit the
different profile I leadership certainly TKIs is is.So, suprachoroidal us, which think I treatments, a And the overall worked leadership I been coming from have entirely clear a are space.I worked completely I out. differentiation stage, been have a meaningful at for profile there chemistry that are commercial as not across think think the what don't think profile. and for we TKIs formulations clinical and don't think this a that necessarily that diseases. a XXX think, onetime well, is retinal that we out have